Chapter 7 Cannabinoid Receptor CB1 Antagonists. State of the Art and Challenges

Vitamins and Hormones

Volumn 81, Issue C, 2009, Pages 159-189

  Bifulco, Maurizio ^a   Santoro, Antonietta ^a   Laezza, Chiara ^b   Malfitano, Anna Maria ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; RIMONABANT;

ANIMAL; ANIMAL MODEL; CLINICAL TRIAL; DRUG ANTAGONISM; ENERGY METABOLISM; HUMAN; OBESITY; PHYSIOLOGY; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; ENDOCANNABINOIDS; ENERGY METABOLISM; HUMANS; MODELS, ANIMAL; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1;

EID: 67651155822     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0083-6729(09)81007-8     Document Type: Review

References (130)

1. Addy C., Wright H., Van Laere K., Gantz I., Erondu N., Musser B.J., Lu K., Yuan J., Sanabria-Bohórquez S.M., Stoch A., Stevens C., Fong T.M., et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 7 (2008) 68-78
2. 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in Adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 63 (2003) 908-914
3. Berry E.M., and Mechoulam R. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol. Ther. 95 (2002) 185-190
4. Bifulco M., and Di Marzo V. Targeting the endocannabinoid system in cancer therapy: A call for further research. Nat. Med. 8 (2002) 547-550
5. Bifulco M., Laezza C., Portella G., Vitale M., Orlando P., De Petrocellis L., and Di Marzo V. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J. 15 (2001) 2745-2747
6. Bifulco M., Laezza C., Valenti M., Ligresti A., Portella G., and Di Marzo V. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J. 18 (2004) 1606-1608
7. Bifulco M., Laezza C., Pisanti S., and Gazzerro P. Cannabinoids and cancer: Pros and cons of an antitumour strategy. Br. J. Pharmacol. 148 (2006) 123-135
8. Bifulco M., Grimaldi C., Gazzerro P., Pisanti S., and Santoro A. Rimonabant: Just an antiobesity drug? Current evidence on its pleiotropic effects. Mol. Pharmacol. 71 (2007) 1445-1456
9. Bifulco M., Gazzerro P., Laezza C., and Pentimalli F. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion. Oncol. Rep. 17 (2007) 813-816
10. Blankman J.L., Simon G.M., and Cravatt B.F. A comprehensive profile of brain enzyme that hydrolize the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14 (2007) 1347-1356
11. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Portier M., Barth F., Calandra B., Pecceu F., Lupker J., Maffrand J.P., Le Fur G., et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272 (1997) 22330-22339
12. Cani P.D., Montoya M.L., Neyrinck A.M., Delzenne N.M., and Lambert D.M. Potential modulation of plasma ghrelin and glucagons-like peptide 1 by anorexigenic cannabinoids compound, SR141716 (rimonabant) and oleoylethanolamide. Br. J. Nutr. 92 (2004) 757-761
13. Cavuoto P., McAincha A.J., Hatzinikolas G., Cameron-Smith D., and Wittert G.A. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol. Cell. Endocrinol. 267 (2007) 63-69
14. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., and Astrup A. Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Lancet 370 (2007) 1706-1713
15. Cianchi F., Papucci L., Schiavone N., Lulli M., Magnelli L., Vinci M.C., Messerini L., Manera C., Ronconi E., Romagnani P., Donnini M., Perigli G., et al. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor α-mediated de novo synthesis in colon cancer cells. Clin. Cancer Res. 14 (2008) 7691-7700
16. Cota D. CB1 receptors: Emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab. Res. Rev. 23 (2007) 507-517
17. Cota D., Marsicano G., Tschoep M., Gruebler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thone-Reineke C., Ortmann S., Tomassoni F., Cervino C., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112 (2003) 423-431
18. Cote M., Matias I., Lemieux I., Petrosino S., Almeras N., Després J.P., and Di Marzo V. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int. J. Obesity 31 (2007) 692-699
19. Curioni C., and Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst. Rev. 4 (2006) CD006162
20. Deedwania P. The endocannabinoid system and cardiometabolic risk: Effects of CB(1) receptor blockade on lipid metabolism. Int. J. Cardiol. 131 (2009) 305-312
21. Derocq J.M., Bouaboula M., Marchand J., Rinaldi-Carmona M., Segui M., and Casellas P. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS Lett. 425 (1998) 419-425
22. Després J.P., and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444 (2006) 881-887
23. Després J.P., Golay A., Sjöström L., and Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353 (2005) 2121-2134
24. Després J.P., Ross R., Boka G., Alméras N., Lemieux I., and ADAGIO-LIPIDS Investigators. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia intraabdominal adiposity and liver fat. The ADAGIO-lipids trial. Arterioscler. Thromb. Vasc. Biol. 29 (2008) 416-423
25. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
26. Di Marzo V. Targeting the endocannabinoid system: To enhance or reduce?. Nat. Rev.Drug Discov. 7 (2008) 438-453
27. Di Marzo V. CB(1) receptor antagonism: Biological basis for metabolic effects. Drug Discov. Today 13 (2008) 1026-1041
28. Di Marzo V. Play an ADAGIO with a STRADIVARIUS: The right patient for CB1 receptor antagonists?. Nat. Clin. Pract. Cardiovasc. Med. 5 10 (2008) 610-612
29. Di Marzo V., and Szallasi A. Rimonabant in rats with a metabolic syndrome: Good news after the depression. Br. J. Pharmacol. 154 (2008) 915-917
30. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., and Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
31. Di Marzo V., Bifulco M., and De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 3 (2004) 771-784
32. Doggrell S.A. Is rimonabant efficacious and safe in the treatment of obesity?. Expert Opin. Pharmacother. 9 (2008) 2727-2731
33. Dol-Gleizes F., Paumelle R., Visentin V., Marés A.M., Desitter P., Hennuyer N., Gilde A., Staels B., Schaeffer P., and Bono F. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 29 (2009) 12-18
34. Esposito I., Proto M.C., Gazzerro P., Laezza C., Miele C., Alberobello A.T., D'Esposito V., Beguinot F., Formisano P., and Bifulco M. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol. Pharmacol. 74 (2008) 1678-1686
35. Flygare J., Gustafsson K., Kimby E., Christensson B., and Sander B. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett. 579 (2005) 6885-6889
36. Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-00-index.htm
37. Freund T.F., Katona I., and Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83 (2003) 1017-1066
38. Gable D.R., Hurel S.J., and Humphries S.E. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis 188 (2006) 231-244
39. Gamber K.M., Macartur H., and Westfall T.C. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology 143 (2005) 520-523
40. Gary-Bobo M., Elachouri G., Scatton B., Le Fur G., Oury-Donat F., and Bensaid M. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol. Pharmacol. 69 (2006) 471-478
41. Gatley S.J., Gifford A.N., Volkow N.D., Lan R., and Makriyannis A. 123I-labeled AM251: A radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur. J. Pharmacol. 307 (1996) 331-338
42. Gessa G.L., Serra S., Vacca G., Carai M.A.M., and Colombo G. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcoholism 40 (2005) 46-53
43. Griffith D.A., Hadcock J.R., Black S.C., Iredale P.A., Carpino P.A., Da Silva-Jardine P., Day R., DiBrino J., Dow R.L., Landis M.S., O'Connor R.E., et al. Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist. J. Med. Chem. 52 (2009) 234-237
44. Grimaldi C., Pisanti C., Laezza C., Malfitano A.M., Santoro A., Vitale M., Caruso M., Notarnicola M., Iacuzzo I., Portella G., Di Marzo V., et al. Anandamide inhibits adhesion and migration of breast cancer cells. Exp. Cell Res. 312 (2006) 363-373
45. Hagmann W.K. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity. Arch. Pharm. (Weinheim) 341 (2008) 405-411
46. Hajos N., and Freund T.F. Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 43 (2002) 503-510
47. Hajos N., Ledent C., and Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106 (2001) 1-4
48. Haller J., Bakos N., Szirmay M., Ledent C., and Freund T.F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur. J. Neurosci. 16 (2002) 1395-1398
49. Haller J., Varga B., Ledent C., and Freund T.F. CB1 cannabinoid receptors mediate anxiolytic effects: Convergent genetic and pharmacological evidence with CB1-specific agents. Behav. Pharmacol. 15 (2004) 299-304
50. Henness S., Robinson D.M., and Lyseng-Williamson K.A. Rimonabant. Drugs 66 (2006) 2109-2119 discussion 2120-2121
51. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA 87 (1990) 1932-1936
52. Herling A.W., Gossel M., Haschke G., Stengelin S., Kuhlmann J., Muller G., Schmoll D., and Kramer W. CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am. J. Physiol. Endocrinol. Metab. 293 (2007) E826-E832
53. Howlett A.C. Cannabinoid receptor signaling. Handbook Exp. Pharmacol. 168 (2005) 53-79
54. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
55. Iranmanesh A., Rosenstock J., Hollander P., and SERENADE Study-Group. SERENADE: Rimonabant monotherapy for treatment of multiple cardiometabolic risk factors in treatment-naive patients with type 2 diabetes. Diabet. Med. 23 Suppl. 4 (2006) 200-410
56. Jacobsson S.O., Wallin T., and Fowler C.J. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther. 299 (2001) 951-959
57. Jagerovic N., Hernandez-Folgado L., Alkorta I., Goya P., Navarro M., Serrano A., Rodriguez de Fonseca F., Dannert M.T., Alsasua A., Suardiaz M., Pascual D., et al. Discovery of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif. J. Med. Chem. 47 (2004) 2939-2942
58. Jamshidi N., and Taylor D.A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br. J. Pharmacol. 134 (2001) 1151-1154
59. Jbilo O., Ravinet-Trillou C., Arnone M., Buisson I., Bribes E., Peleraux A., Pénarier G., Soubrié P., Le Fur G., Galiègue S., and Casellas P. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 19 (2005) 1567-1569
60. Kang S.Y., Lee S., Seo H.J., Jung M.E., Ahn K., Kim J., and Lee J. Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists. Bioorg. Med. Chem. Lett. 18 (2008) 2385-2389
61. Kim J.Y., Seo H.J., Lee S.H., Jung M.E., Ahn K., Kim J., and Lee J. Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists. Bioorg. Med. Chem. Lett. 19 (2009) 142-145
62. Kirkham T.C., Williams C.M., Fezza F., and Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation on eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. 136 (2002) 550-557
63. Kola B., Farkas I., Christ-Crain M., Wittmann G., Lolli F., Amin F., Harvey-White J., Liposits Z., Kunos G., Grossman A.B., Fekete C., et al. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS ONE 12 (2008) e1797
64. Lallemand F., and De Witte P. SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats. Alcohol 39 (2006) 125-134
65. Lan R., Liu Q., Fan P., Lin S., Fernando S.R., McCallion D., Pertwee R., and Makriyannis A. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem. 42 (1999) 769-776
66. Lange J.H., and Kruse C.G. Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives. Chem. Rec. 8 (2008) 156-168
67. Lin L.S., Lanza T.J., Jewell J.P., Liu P., Shah S.K., Qi H., Tong X., Wang J., Xu S.S., Fong T.M., Shen C.P., Lao J., et al. Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J. Med. Chem. 49 (2006) 7584-7587
68. Liu Y.L., Connoley I.P., Wilson C.A., and Stock M.J. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int. J. Obesity 29 (2005) 183-187
69. Liu J., Wang L., Harvey-White J., Huang B.X., Kim H.Y., Luquet S., Palmiter R.D., Krystal G., Rai R., Mahadevan A., Razdan R.K., et al. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 54 (2008) 1-7
70. Maccarrone M., Lorenzon T., Bari M., Melino G., and Finazzi-Agrò A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 275 (2000) 31938-31945
71. Malfitano A.M., Matarese G., Pisanti S., Grimaldi C., Laezza C., Bisogno T., Di Marzo V., Lechler R.I., and Bifulco M. Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. J. Neuroimmunol. 171 (2006) 110-119
72. Malfitano A.M., Toruner G.A., Gazzerro P., Laezza C., Husain S., Eletto D., Orlando P., De Petrocellis L., Terskiy A., Schwalb M., Vitale E., et al. Arvanil and anandamide up-regulate CD36 expression in human peripheral blood mononuclear cells. Immunol. Lett. 109 (2007) 145-154
73. Malfitano A.M., Laezza C., Pisanti S., Gazzerro P., and Bifulco M. Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells. Br. J. Pharmacol. 153 (2008) 1003-1010
74. Matias I., and Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol. Metab. 18 (2007) 27-37
75. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocellis L., Cervino C., Petrosino S., Hoareau L., Festy F., Pasquali R., Roche R., Maj M., et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and b-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 91 (2006) 3171-3180
76. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
77. Melis M., Pistis M., Perra S., Muntoni A.L., Pillolla G., and Gessa G.L. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J. Neurosci. 24 (2004) 53-62
78. Muccioli G.G., Wouters J., Scriba G.K.E., Poppitz W., Poupaert J.H., and Lambert D.M. 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: New templates among the CB1 cannabinoid receptor inverse agonists. J. Med. Chem. 48 (2005) 7486-7490
79. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
80. Nesto R.W. Managing cardiovascular risk in patients with metabolic syndrome. Clin. Cornerstone 7 (2005) 46-51
81. Nissen S.E., Nicholls S.J., Wolski K., Rodés-Cabau J., Cannon C.P., Deanfield J.E., Després J.P., Kastelein J.J., Steinhubl S.R., Kapadia S., Yasin M., Ruzyllo W., et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease The STRADIVARIUS randomized controlled trial. JAMA 299 13 (2008) 1547-1560
82. Nogueiras R., Veyrat-Durebex C., Suchanek P.M., Klein M., Tschöp J., Caldwell C., Woods S.C., Wittmann G., Watanabe M., Liposits Z., Fekete C., Reizes O., et al. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 57 (2008) 2977-2991
83. Osei-Hyiaman D., Depetrillo M., Harvey-White J., Bannon A.W., Cravatt B.F., Kuhar M.J., Mackie K., Palkovits M., and Kunos G. Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of anandamide. Neuroendocrinology 81 (2005) 273-282
84. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Batkai S., Harvey-White J., Mackie K., Offertaler L., Wang L., and Kunos G. Endocannabinoids activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet induced obesity. J. Clin. Invest. 115 (2005) 1298-1305
85. Pacher P., Batkai S., and Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58 (2006) 389-462
86. Padwal R.S., and Majumdar S.R. Drug treatments for obesity: Orlistat, sibutramine, and rimonabant. Lancet 369 (2007) 71-77
87. Pagotto U., Marsicano G., Cota D., Lutz B., and Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 27 (2006) 73-100
88. Pamplona F.A., and Takahashi R.N. WIN 55212-2 impairs contextual fear conditioning through the activation of CB1 cannabinoid receptors. Neurosci. Lett. 397 (2006) 88-92
89. Pavon F.J., Bilbao A., Hernandez-Folgado L., Cippitelli A., Jagerovic N., Abellan G., Rodriguez-Franco M.A., Serrano A., Macias M., Gomez R., Navarro M., Goya P., et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole-LH-21. Neuropharmacology 51 (2006) 358-366
90. Pavon F.J., Serrano A., Pérez-Valero V., Jagerovic N., Hernandez-Folgado L., Bermudez-Silva F.J., Macias M., Goya M., and Rodriguez de Fonseca F. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: Effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J. Neuroendocrinol. 20 (2008) 116-123
91. Pertwee R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 63 (2001) 569-611
92. Pertwee R.G. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci. 76 (2005) 1307-1324
93. Piomelli D., Giuffrida A., Calignano A., and de Fonseca F.R. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci. 21 (2000) 218-224
94. Pi-Sunyer X.F., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J., and RIO-North America Study Group. Effect of Rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: A randomized controlled trial. JAMA 295 (2006) 761-775
95. Portella G., Laezza C., Laccetti P., De Petrocellis L., Di Marzo V., and Bifulco M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: Actions on signals involved in angiogenesis and metastasis. FASEB J. 17 (2003) 1771-1773
96. Powles T., Poele R., Shamash J., Chaplin T., Propper D., Joel S., Oliver T., and Liu W.M. Cannabis-induced cytotoxicity in leukemic cell lines: The role of the cannabinoid receptors and the MAPK pathway. Blood 105 (2005) 1214-1221
97. Rajesh M., Mukhopadhyay P., Haskó G., and Pacher P. Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation. Biochem. Biophys. Res. Commun. 377 (2008) 1248-1252
98. Ravinet Trillou C., Arnone M., Delgorge C., Gonalons N., Keane P., Maffrand J.P., and Soubrié P. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Regul. Integr. Comp. Physiol. 284 (2003) R345-R353
99. Rinaldi-Carmona M., Barth F., Healume M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350 (1994) 240-244
100. Rinaldi-Carmona M., Barth F., Heaulme M., Alonso R., Shire D., Congy C., Soubrie P., Breliere J.C., and Le Fur G. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 56 (1995) 1941-1947
101. Rinaldi-Carmona M., Barth F., Congy C., Martinez S., Oustric D., Perio A., Poncelet M., Maruani J., Arnone M., Finance O., Soubrie P., et al. SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: Biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. 310 (2004) 905-914
102. Rodriguez de Fonseca F., Navarro M., Gomez R., Escuredo L., Nava F., Fu J., Murillo-Rodriguez E., Giuffrida A., LoVerme J., Gaetani S., Kathuria S., Gall C., et al. An anorexic lipid mediator regulated by feeding. Nature 414 (2001) 209-212
103. Rosenstock J., Hollander P., Chevalier S., Iranmanesh A., and SERENADE Study Group. SERENADE: The study evaluating rimonabant efficacy in drug-naive diabetic patients: Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 31 (2008) 2169-2176
104. Rucker D., Padwal R., Li S.K., Curioni C., and Lau D.C. Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. BMJ 335 (2007) 1194-1199
105. Ruilope L.M., Després J.P., Scheen A., Pi-Sunyer X., Mancia G., Zanchetti A., and Van Gaal L. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: Analysis of pooled RIO study results. J. Hypertens. 26 (2008) 357-367
106. Sanchez C., de Ceballos M.L., del Pulgar T.G., Rueda D., Corbacho C., Velasco G., Galve-Roperh I., Huffman J.W., Ramon y Cajal S., and Guzman M. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 61 (2001) 5784-5789
107. Santoro A., Gazzerro P., Malfitano A.M., Pisanti S., Laezza C., and Bifulco M. Reply to the letter to the editor "Long-term cannabinoid receptor (CB1) blockade in obesity: Implications for the development of colorectal cancer". Int. J. Cancer 122 (2008) 243-244
108. Sarfaraz S., Afaq F., Adhami V.M., and Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 65 (2005) 1635-1641
109. Sarnataro D., Pisanti S., Santoro A., Gazzerro P., Malfitano A.M., Laezza C., and Bifulco M. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid rafts mediated mechanism. Mol. Pharmacol. 70 (2006) 1298-1306
110. Savinainen J.R., Saario S.M., Niemi R., Järvinen T., and Laitinen J.T. An optimized approach to study endocannabinoid signaling: Evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. Br. J. Pharmacol. 140 (2003) 1451-1459
111. Schäfer A., Pfrang J., Neumüller J., Fiedler S., Ertl G., and Bauersachs J. The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br. J. Pharmacol. 154 (2008) 1047-1054
112. Scheen A.J., and Paquot N. Inhibitors of cannabinoid receptors and glucose metabolism. Curr. Opin. Clin. Nutr. Metab. Care 11 (2008) 505-511
113. Scheen A.J., Fine N., Hollander P., Jensen M.D., Van Gaal L.F., and RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomized controlled study. Lancet 368 (2006) 1660-1672
114. Scheen A.J., Van Gaal L.F., Després J.P., Pi-Sunyer X., Golay A., and Hanotin C. Le rimonabant améliore le profil de risque cardio-métabolique chez le sujet obèse ou en surpoids: Synthèse des études "RIO". Rev. Med. Suisse 2 (2006) 1916-1923
115. Serra G., and Fratta W. A possible role for the endocannabinoid system in the neurobiology of depression. Clin. Pract. Epidemiol. Mental Health 3 (2007) 25 doi:10.1186/1745-0179-3-25
116. Sugamura K., Sugiyama S., Nozaki T., Matsuzawa Y., Izumiya Y., Miyata K., Nakayama M., Kaikita K., Obata T., Takeya M., and Ogawa H. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 119 (2009) 28-36
117. Tedesco L., Valerio A., Cervino C., Cardile A., Pagano C., Vettor R., Pasquali R., Carruba M.O., Marsicano G., Lutz B., Pagotto U., et al. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes 57 (2008) 2028-2036
118. Tucci S.A., Rogers E.K., Korbonits M., and Kirlham T.C. The cannabinoid receptor antagonist SR141716 blocks the orexigenic effect of intrahypothalamic ghrelin. Br. J. Pharmacol. 143 (2004) 520-523
119. Van Gaal L.F., Rissanen A.M., Scheen A., Ziegler O., Rössner S., and RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
120. Van Gaal L.F., Mertens I.L., and De Block C.E. Mechanisms linking obesity with cardiovascular disease. Nature 444 (2006) 875-880
121. Van Gaal L.F., Pi-Sunyer X., Després J.P., Mc Carthy C., and Scheen A.J. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: Pooled 1-year data from the RIO program. Diabetes Care 31 Suppl. 2 (2008) S229-S240
122. Van Gaal L.F., Scheen A.J., Rissanen A.M., Rössner S., Hanotin C., Ziegler O., and RIO-Europe Study Group. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: Two year results from the RIO-Europe Study. Eur. Heart J. 29 (2008) 1761-1771
123. Verty A.N., McFarlane J.R., McGregor I.S., and Mallet P.E. Evidence for an interaction between CB1 cannabinoid and melanocortin MC4 receptors in regulating food intake. Endocrinology 145 (2004) 3224-3231
124. Verty A.N., Allen A.M., and Oldfield B.J. The effects of rimonabant on brown adipose tissue in rat: Implications for energy expenditure. Obesity (Silver Spring) 17 (2009) 254-261
125. Wang J., and Ueda N. Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat. (2008) (in press)
126. Wang D., Wang H., Ning W., Backlun M.G., Dey S., and DuBois R. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res. 68 (2008) 6468-6476
127. Watanabe T., Kubota N., Ohsugi M., Kubota T., Takamoto I., Iwabu M., Awazawa M., Katsuyama H., Hasegawa C., Tokuyama K., Moroi M., Sugi K., et al. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. J. Biol. Chem. 284 (2009) 1803-1812
128. Wilson R.I., and Nicoll R.A. Endocannabinoids signaling in the brain. Science 296 (2002) 678-682
129. Wright S.M., Dikkers C., and Aronne L.J. Rimonabant: New data and emerging experience. Curr. Atheroscler. Rep. 10 (2008) 71-78
130. Yo J.H., Chen Y.J., Talmage D.A., and Role L.W. Integration of leptin signalling in an appetite-related neural circuit. Neuron 48 (2005) 1055-1066